{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:46:02Z","timestamp":1793702762711,"version":"4.5.1"},"reference-count":199,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AR060781"],"award-info":[{"award-number":["K01AR060781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR068974"],"award-info":[{"award-number":["R01AR068974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI42269"],"award-info":[{"award-number":["R01AI42269"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI49954"],"award-info":[{"award-number":["R37AI49954"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI068787"],"award-info":[{"award-number":["R01AI068787"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI085567"],"award-info":[{"award-number":["R01AI085567"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR064350"],"award-info":[{"award-number":["R01AR064350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.molmed.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T10:31:06Z","timestamp":1497349866000},"page":"615-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":418,"title":["Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective"],"prefix":"10.1016","volume":"23","author":[{"given":"Vaishali R.","family":"Moulton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Suarez-Fueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Meidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2017.05.006_bib0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2016.08.001","article-title":"The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned","volume":"74","author":"Teruel","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1172\/JCI78087","article-title":"T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity","volume":"125","author":"Moulton","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.05.006_bib0025","first-page":"716","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0035","first-page":"169","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","article-title":"Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies","volume":"74","author":"Lu","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0045","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0050","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/art.39706","article-title":"Autoantibody-positive healthy individuals display unique immune profiles that may regulate autoimmunity","volume":"68","author":"Slight-Webb","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0055","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/jamainternmed.2015.3528","article-title":"Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families","volume":"175","author":"Kuo","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-016-0621-9","article-title":"Monogenic lupus","volume":"18","author":"Lo","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.gene.2013.08.051","article-title":"Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population","volume":"533","author":"Zhang","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.molmed.2017.05.006_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/gene.2014.73","article-title":"Genetic association of CD247 (CD3zeta) with SLE in a large-scale multiethnic study","volume":"16","author":"Martins","year":"2015","journal-title":"Genes Immun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2013.78","article-title":"Gene-function studies in systemic lupus erythematosus","volume":"9","author":"Crispin","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0080","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/ard.2008.097642","article-title":"STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk","volume":"68","author":"Abelson","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0085","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/ng.3434","article-title":"Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus","volume":"47","author":"Bentham","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2017.05.006_bib0090","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.05.006_bib0105","doi-asserted-by":"crossref","first-page":"e0141171","DOI":"10.1371\/journal.pone.0141171","article-title":"T cell transcriptomes describe patient subtypes in systemic lupus erythematosus","volume":"10","author":"Bradley","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2017.05.006_bib0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molmed.2016.04.005","article-title":"Introducing a new dimension to molecular disease classifications","volume":"22","author":"Jourde-Chiche","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0115","first-page":"1003","article-title":"Mapping eQTLs with RNA-seq reveals novel susceptibility genes, non-coding RNAs and alternative-splicing events in systemic lupus erythematosus","volume":"26","author":"Odhams","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2017.05.006_bib0120","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.4049\/jimmunol.1300634","article-title":"T cell CD3zeta deficiency enables multiorgan tissue inflammation","volume":"191","author":"Deng","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0125","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.4049\/jimmunol.181.6.4019","article-title":"Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation","volume":"181","author":"Deng","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting Syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11926-016-0622-8","article-title":"Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years","volume":"18","author":"Oaks","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0140","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0145","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.1301005","article-title":"Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus","volume":"191","author":"Lai","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0150","first-page":"74","article-title":"Systemic lupus erythematosus in 2015: cellular and metabolic requirements of effector T cells","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0155","doi-asserted-by":"crossref","first-page":"274ra218","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0160","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0165","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11306-015-0772-0","article-title":"Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin","volume":"11","author":"Perl","year":"2015","journal-title":"Metabolomics"},{"key":"10.1016\/j.molmed.2017.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/1529-0131(200106)44:6<1336::AID-ART226>3.0.CO;2-8","article-title":"T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations\/polymorphisms and splice variants of T cell receptor zeta chain messenger RNA","volume":"44","author":"Nambiar","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0175","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.27385","article-title":"Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity","volume":"62","author":"Crispin","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0180","doi-asserted-by":"crossref","first-page":"12993","DOI":"10.1038\/ncomms12993","article-title":"ICER is requisite for Th17 differentiation","volume":"7","author":"Yoshida","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.20101653","article-title":"A novel isoform of the Ly108 gene ameliorates murine lupus","volume":"208","author":"Keszei","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0190","doi-asserted-by":"crossref","first-page":"12490","DOI":"10.1074\/jbc.M109.091660","article-title":"Alternative splicing factor\/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex","volume":"285","author":"Moulton","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.05.006_bib0195","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1073\/pnas.1214207110","article-title":"Splicing factor SF2\/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription","volume":"110","author":"Moulton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4161\/rna.7.4.12301","article-title":"Alternative splicing in multiple sclerosis and other autoimmune diseases","volume":"7","author":"Evsyukova","year":"2010","journal-title":"RNA Biol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0205","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","article-title":"IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4\u2212CD8\u2212 IL-17-producing T cells","volume":"193","author":"Mizui","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0210","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-dose IL-2 in the treatment of lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0220","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1400931","article-title":"IL-17 promotes murine lupus","volume":"193","author":"Amarilyo","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0225","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ni1552","article-title":"Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice","volume":"9","author":"Hsu","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clim.2015.04.004","article-title":"Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL\/lpr mice","volume":"158","author":"Edwards","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0235","doi-asserted-by":"crossref","first-page":"43429","DOI":"10.1074\/jbc.M111.299339","article-title":"cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus","volume":"286","author":"Hedrich","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.05.006_bib0240","doi-asserted-by":"crossref","first-page":"16606","DOI":"10.1073\/pnas.1210129109","article-title":"cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus","volume":"109","author":"Hedrich","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0245","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.05.006_bib0250","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.37934","article-title":"Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus","volume":"65","author":"Isgro","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0255","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4049\/jimmunol.178.3.1938","article-title":"Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus","volume":"178","author":"Li","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0260","first-page":"337","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0265","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3554","article-title":"TFH cells progressively differentiate to regulate the germinal center response","volume":"17","author":"Weinstein","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0270","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1196\/annals.1423.063","article-title":"Treatment of BXSB-Yaa mice with IL-21R\u2013Fc fusion protein minimally attenuates systemic lupus erythematosus","volume":"1110","author":"Bubier","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2017.05.006_bib0275","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.1200318","article-title":"IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4T cell- and B cell-intrinsic mechanisms","volume":"189","author":"Nguyen","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0280","doi-asserted-by":"crossref","first-page":"13957","DOI":"10.1038\/ncomms13957","article-title":"Death receptor 6 contributes to autoimmunity in lupus-prone mice","volume":"8","author":"Fujikura","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0285","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1084\/jem.20080840","article-title":"ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity","volume":"205","author":"Odegard","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0290","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3899\/jrheum.131025","article-title":"Increased interleukin 21 and follicular helper T-like cells and reduced interleukin 10+ B cells in patients with new-onset systemic lupus erythematosus","volume":"41","author":"Wang","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0295","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0300","doi-asserted-by":"crossref","first-page":"14432","DOI":"10.1038\/srep14432","article-title":"Hyperactivation and in situ recruitment of inflammatory Vdelta2T cells contributes to disease pathogenesis in systemic lupus erythematosus","volume":"5","author":"Yin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0305","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/eji.201344280","article-title":"Regulatory T cells in systemic lupus erythematosus","volume":"45","author":"Ohl","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0310","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nri3464","article-title":"The plasticity and stability of regulatory T cells","volume":"13","author":"Sakaguchi","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0315","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.molmed.2016.07.003","article-title":"Empowering regulatory T cells in autoimmunity","volume":"22","author":"Kasper","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0320","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/db15-0188","article-title":"Therapeutic window of interleukin-2 for autoimmune diseases","volume":"64","author":"Tang","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2017.05.006_bib0325","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.1201785","article-title":"Calcium\/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus","volume":"189","author":"Koga","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0330","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/ni.3288","article-title":"Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling","volume":"16","author":"Charbonnier","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0335","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1073\/pnas.1607101113","article-title":"Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation","volume":"113","author":"Lourenco","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0340","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.4049\/jimmunol.1301859","article-title":"Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4\u2212CD8\u2212 double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus","volume":"192","author":"Kato","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0345","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ni.3390","article-title":"Phosphatase PP2A is requisite for the function of regulatory T cells","volume":"17","author":"Apostolidis","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0350","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaut.2013.06.004","article-title":"Promotion and prevention of autoimmune disease by CD8+ T cells","volume":"45","author":"Gravano","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0355","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/art.39410","article-title":"Selective loss of signaling lymphocytic activation molecule family member 4-positive CD8+ T cells contributes to the decreased cytotoxic cell activity in systemic lupus erythematosus","volume":"68","author":"Kis-Toth","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0360","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.4049\/jimmunol.1402775","article-title":"Programmed cell death 1 and Helios distinguish TCR-alphabeta+ double-negative (CD4\u2212CD8\u2212) T cells that derive from self-reactive CD8T cells","volume":"194","author":"Rodriguez-Rodriguez","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0365","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2004-08-3269","article-title":"SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells","volume":"105","author":"Dupre","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2017.05.006_bib0370","doi-asserted-by":"crossref","first-page":"1058165","DOI":"10.1155\/2016\/1058165","article-title":"CD3+CD8+CD28\u2212 T lymphocytes in patients with lupus nephritis","volume":"2016","author":"Zabinska","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.molmed.2017.05.006_bib0375","doi-asserted-by":"crossref","DOI":"10.1002\/art.40038","article-title":"SLAMF7 engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus","author":"Comte","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-016-0571-2","article-title":"Mortality in systemic lupus erythematosus: an updated review","volume":"18","author":"Fors Nieves","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0385","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14656566.2014.894976","article-title":"Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments","volume":"15","author":"Liossis","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.molmed.2017.05.006_bib0390","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.4049\/jimmunol.178.10.6624","article-title":"A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus","volume":"178","author":"Wei","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0395","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molmed.2009.12.005","article-title":"Pathogenesis of human systemic lupus erythematosus: recent advances","volume":"16","author":"Crispin","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2017.05.006_bib0405","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00281-014-0430-z","article-title":"Rationale for B cell targeting in SLE","volume":"36","author":"Sanz","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0410","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/art.38138","article-title":"9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus","volume":"65","author":"Jenks","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0415","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.07.002","article-title":"DNA-reactive B cells in lupus","volume":"43","author":"Suurmond","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0425","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.2439","article-title":"CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation","volume":"44","author":"Manjarrez-Orduno","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2017.05.006_bib0430","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0961203316643172","article-title":"B-cell subsets, signaling and their roles in secretion of autoantibodies","volume":"25","author":"Iwata","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2017.05.006_bib0435","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.immuni.2012.11.017","article-title":"Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus","volume":"38","author":"Teichmann","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2017.05.006_bib0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0445","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0450","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.coi.2013.10.006","article-title":"TLRs and interferons: a central paradigm in autoimmunity","volume":"25","author":"Kono","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0455","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","article-title":"The role of complement in the development of systemic lupus erythematosus","volume":"22","author":"Manderson","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0460","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/imr.12348","article-title":"SLE-associated risk factors affect DC function","volume":"269","author":"Son","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0465","first-page":"151","article-title":"Macrophage subpopulations in systemic lupus erythematosus","volume":"13","author":"Orme","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0470","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases","volume":"8","author":"Gilliet","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0475","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2010.63","article-title":"Genetics of SLE: evidence from mouse models","volume":"6","author":"Morel","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0480","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni.3253","article-title":"Phagocytosis of apoptotic cells in homeostasis","volume":"16","author":"Arandjelovic","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0485","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrrheum.2010.64","article-title":"Cytokines as therapeutic targets in SLE","volume":"6","author":"Ronnblom","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0490","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.21783","article-title":"Impaired recognition of apoptotic neutrophils by the C1q\/calreticulin and CD91 pathway in systemic lupus erythematosus","volume":"54","author":"Donnelly","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0495","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/ar3528","article-title":"Mechanisms of tissue injury in lupus nephritis","volume":"13","author":"Nowling","year":"2011","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.molmed.2017.05.006_bib0500","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.05.006_bib0505","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0510","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1136\/annrheumdis-2014-205365","article-title":"Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL\/lpr mice","volume":"74","author":"Knight","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0515","doi-asserted-by":"crossref","first-page":"157ra141","DOI":"10.1126\/scitranslmed.3004801","article-title":"NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus","volume":"4","author":"Campbell","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0520","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0525","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcdb.2014.04.020","article-title":"Modulation of tolerogenic dendritic cells and autoimmunity","volume":"41","author":"Kim","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0530","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar3206","article-title":"Disturbances of apoptotic cell clearance in systemic lupus erythematosus","volume":"13","author":"Shao","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2017.05.006_bib0535","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature06307","article-title":"Identification of Tim4 as a phosphatidylserine receptor","volume":"450","author":"Miyanishi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.05.006_bib0540","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/417182a","article-title":"Identification of a factor that links apoptotic cells to phagocytes","volume":"417","author":"Hanayama","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.05.006_bib0545","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ni.2670","article-title":"The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity","volume":"14","author":"Ramirez-Ortiz","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0550","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","article-title":"The complement system in systemic lupus erythematosus: an update","volume":"73","author":"Leffler","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0555","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.194.6.781","article-title":"C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells","volume":"194","author":"Ogden","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0560","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1084\/jem.20110658","article-title":"Tolerogenic function of Blimp-1 in dendritic cells","volume":"208","author":"Kim","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0565","first-page":"823","article-title":"Regulation of dendritic cell activation by microRNA let-7c and BLIMP1","volume":"123","author":"Kim","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.05.006_bib0570","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","article-title":"Development and function of dendritic cell subsets","volume":"40","author":"Mildner","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2017.05.006_bib0575","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2009.278","article-title":"Sensors of the innate immune system: their link to rheumatic diseases","volume":"6","author":"Theofilopoulos","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0580","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.coi.2012.08.004","article-title":"Complement, interferon and lupus","volume":"24","author":"Elkon","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0585","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/MCB.01430-12","article-title":"Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands","volume":"33","author":"Apelbaum","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0590","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.189.3.521","article-title":"Type I interferons keep activated T cells alive","volume":"189","author":"Marrack","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0595","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.05.006_bib0600","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.immuni.2014.05.004","article-title":"Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity","volume":"40","author":"Xu","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2017.05.006_bib0605","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1084\/jem.20092695","article-title":"Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response","volume":"207","author":"Swanson","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0610","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.4049\/jimmunol.181.9.5875","article-title":"Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha","volume":"181","author":"Uccellini","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0615","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4049\/jimmunol.0900870","article-title":"Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity","volume":"184","author":"Wang","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0620","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature04606","article-title":"CD69 acts downstream of interferon-alpha\/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs","volume":"440","author":"Shiow","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.05.006_bib0625","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI81059","article-title":"Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus","volume":"125","author":"Li","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.05.006_bib0630","doi-asserted-by":"crossref","first-page":"e102151","DOI":"10.1371\/journal.pone.0102151","article-title":"Dysregulated cytokine production by dendritic cells modulates B cell responses in the NZM2410 mouse model of lupus","volume":"9","author":"Sang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2017.05.006_bib0635","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon-alpha\/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0640","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0645","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2017.05.006_bib0650","doi-asserted-by":"crossref","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","article-title":"Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"2","author":"Duffau","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0655","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/art.11237","article-title":"Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus","volume":"48","author":"Ren","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0660","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K","article-title":"Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus","volume":"46","author":"Baumann","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0665","first-page":"543","article-title":"The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases","volume":"12","author":"Cuda","year":"2016","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0670","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.1300041","article-title":"Cutting Edge: defective follicular exclusion of apoptotic antigens due to marginal zone macrophage defects in autoimmune BXD2 mice","volume":"190","author":"Li","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0675","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/ncb3192","article-title":"Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins","volume":"17","author":"Martinez","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0680","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature17950","article-title":"Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells","volume":"533","author":"Martinez","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.05.006_bib0685","first-page":"663","article-title":"Pathogenesis and targeted treatment of skin injury in SLE","volume":"11","author":"Deng","year":"2015","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0690","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00467-011-2078-4","article-title":"Autoantibodies in systemic lupus erythematosus","volume":"27","author":"Marks","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0695","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0700","article-title":"Pathogenesis of proliferative lupus nephritis from a historical and personal perspective","author":"Fu","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0705","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1084\/jem.20130731","article-title":"Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis","volume":"210","author":"Ge","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0710","first-page":"705","article-title":"Future prospects in biologic therapy for systemic lupus erythematosus","volume":"9","author":"Stohl","year":"2013","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-016-0589-5","article-title":"Update on biologic therapies for systemic lupus erythematosus","volume":"18","author":"Borba","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2017.05.006_bib0720","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.06.014","article-title":"Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis","volume":"74","author":"Gatto","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0725","article-title":"Lupus nephritis biomarkers","author":"Soliman","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0730","first-page":"221","article-title":"Towards new avenues in the management of lupus glomerulonephritis","volume":"12","author":"Mok","year":"2016","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0735","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0961203316640367","article-title":"Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care","volume":"25","author":"Choi","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2017.05.006_bib0740","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/BOR.0000000000000199","article-title":"Preclinical lupus","volume":"27","author":"Bourn","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0745","first-page":"8791629","article-title":"Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment","volume":"2016","author":"Olsen","year":"2016","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0750","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23201","article-title":"Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls","author":"Aberle","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.molmed.2017.05.006_bib0755","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0760","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2017.05.006_bib0765","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0770","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.molmed.2017.05.006_bib0775","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0780","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0785","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0790","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1002\/art.23673","article-title":"Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized controlled phase III trial","volume":"58","author":"Cardiel","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0795","series-title":"UCB Announces Phase 3 clinical trial program for epratuzumab in systemic lupus erythematosus did not meet primary endpoint","author":"UCB","year":"2015"},{"key":"10.1016\/j.molmed.2017.05.006_bib0800","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0805","series-title":"ACR\/ARHP Annual Meeting","article-title":"Safety and efficacy of Sifalimumab, an anti-IFN alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE)","author":"Khamashta","year":"2014"},{"key":"10.1016\/j.molmed.2017.05.006_bib0810","series-title":"Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints","author":"AstraZeneca","year":"2015"},{"key":"10.1016\/j.molmed.2017.05.006_bib0815","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0820","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0825","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus","volume":"67","author":"Welcher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0830","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0835","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0840","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2017.05.006_bib0845","doi-asserted-by":"crossref","first-page":"e000146","DOI":"10.1136\/lupus-2016-000146","article-title":"Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus","volume":"3","author":"Sullivan","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0850","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0855","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0860","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1136\/annrheumdis-2013-eular.528","article-title":"A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care","volume":"72","author":"Jayne","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0865","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.33493","volume":"64","author":"Bengtsson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0870","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","article-title":"Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial","volume":"72","author":"Zimmer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2017.05.006_bib0875","series-title":"ACR\/ARHP Annual Meeting","author":"Tillmann","year":"2014"},{"key":"10.1016\/j.molmed.2017.05.006_bib0880","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.clinthera.2013.06.008","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis","volume":"35","author":"Wisniacki","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.molmed.2017.05.006_bib0885","first-page":"635","article-title":"The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases","volume":"6","author":"Khan","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0890","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clim.2012.04.003","article-title":"Why do women get lupus?","volume":"144","author":"Moulton","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0895","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.20070850","article-title":"A role for sex chromosome complement in the female bias in autoimmune disease","volume":"205","author":"Smith-Bouvier","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0900","first-page":"740","article-title":"Modulation of autoimmune rheumatic diseases by oestrogen and progesterone","volume":"10","author":"Hughes","year":"2014","journal-title":"Nat. Rev."},{"key":"10.1016\/j.molmed.2017.05.006_bib0905","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.040577497","article-title":"Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells","volume":"97","author":"Bynoe","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0910","first-page":"2644","article-title":"Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus","volume":"28","author":"Rider","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0915","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2119\/molmed.2011.00506","article-title":"Estrogen upregulates cyclic AMP response element modulator alpha expression and downregulates interleukin-2 production by human T lymphocytes","volume":"18","author":"Moulton","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0920","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clim.2008.03.508","article-title":"Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse","volume":"128","author":"Svenson","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0925","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2016.10.011","article-title":"Estrogen receptor alpha promotes lupus in (NZB\u00d7NZW)F1 mice in a B cell intrinsic manner","volume":"174","author":"Tabor","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0930","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaut.2013.01.005","article-title":"Impaired DNA methylation and its mechanisms in CD4+ T cells of systemic lupus erythematosus","volume":"41","author":"Zhang","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0935","doi-asserted-by":"crossref","first-page":"21936","DOI":"10.1074\/jbc.M113.467266","volume":"288","author":"Sunahori","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.05.006_bib0940","doi-asserted-by":"crossref","first-page":"e1003678","DOI":"10.1371\/journal.pgen.1003678","article-title":"Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations","volume":"9","author":"Absher","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molmed.2017.05.006_bib0945","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaut.2013.04.003","article-title":"Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients","volume":"43","author":"Coit","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0950","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/pr050188r","article-title":"Resetting the epigenetic histone code in the MRL-lpr\/lpr mouse model of lupus by histone deacetylase inhibition","volume":"4","author":"Garcia","year":"2005","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.molmed.2017.05.006_bib0955","first-page":"804","article-title":"Abnormal histone modification patterns in lupus CD4+ T cells","volume":"35","author":"Hu","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2017.05.006_bib0960","doi-asserted-by":"crossref","first-page":"43437","DOI":"10.1074\/jbc.M111.299313","article-title":"cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus","volume":"286","author":"Rauen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.05.006_bib0965","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1073\/pnas.0712051105","article-title":"HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen","volume":"105","author":"Li","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.05.006_bib0970","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2119\/molmed.2011.00055","article-title":"HDAC inhibition in lupus models","volume":"17","author":"Reilly","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.molmed.2017.05.006_bib0975","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0961203314552117","article-title":"Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients","volume":"24","author":"Lashine","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2017.05.006_bib0980","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.24436","article-title":"MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins","volume":"60","author":"Tang","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2017.05.006_bib0985","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.06.020","article-title":"The critical role of epigenetics in systemic lupus erythematosus and autoimmunity","volume":"74","author":"Long","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2017.05.006_bib0990","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.05.006_bib0995","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","article-title":"T cells in systemic lupus erythematosus","volume":"43","author":"Suarez-Fueyo","year":"2016","journal-title":"Curr. Opin. Immunol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:43:50Z","timestamp":1750329830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491417300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":199,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1471491417300849"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2017.05.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}